Phase II trial of trimetrexate for patients with advanced gastric carcinoma : An Eastern Cooperative Oncology Group Study (E1287)

✍ Scribed by Ramesh K. Ramanathan; Stuart Lipsitz; Robert F. Asbury; Raman Qazi; Bernard R. Greenberg; Daniel G. Haller

• Publisher: John Wiley and Sons
• Year: 1999
• Tongue: English
• Weight: 65 KB
• Volume: 86
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19990815)86:4<572::aid-cncr5>3.0.co;2-#

✦ Synopsis

BACKGROUND.

A Phase II study was conducted to evaluate the response, duration of response, and duration of survival of patients with measurable gastric carcinoma treated with trimetrexate (TMTX) who had not had prior chemotherapy.

METHODS.

Thirty-three patients with unresectable or metastatic gastric adenocarcinoma who had not received previous chemotherapy were treated with intravenous TMTX 12 mg/m 2 daily for 5 days. The dosage of TMTX was reduced to 8 mg/m 2 daily for 5 days for those who had received prior radiotherapy. The cycle was repeated every 3 weeks until disease progression or unacceptable toxicity occurred.

RESULTS.

Thirty-three patients could be analyzed with follow-up data. There was one Grade 5 (lethal) toxicity and four Grade 4 toxicities. Hematologic toxicity was the most common. The overall response rate was 21%, the overall median progression free survival was 2.7 months, and the overall median survival was 5.9 months for the entire cohort. No patients were alive at last follow-up.

CONCLUSIONS.

Though TMTX as a single agent has activity in gastric carcinoma with manageable toxicity, it cannot be recommended for routine use as a single agent due to the brief duration of response and median survival. Cancer 1999;86: 572-6.